Jevtana

Cabazitaxel, the active ingredient in Jevtana, is a taxane (microtubule inhibitor) presented as an injectable solution for intravenous use. It treats metastatic castration‑resistant prostate cancer in patients whose disease has progressed after prior chemotherapy. The drug is approved in the European Union and is administered under the supervision of a qualified healthcare professional.

GNH USA supplies Jevtana as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution.

Cabazitaxel is indicated for the treatment of advanced prostate cancer that no longer responds to hormonal therapy and has progressed after prior chemotherapy.

Metastatic castration‑resistant prostate cancer: improves overall survival and delays disease progression in patients previously treated with docetaxel. Patients previously treated with docetaxel: offers a taxane alternative that can overcome resistance. Hormone‑refractory prostate cancer: used when disease progresses despite androgen deprivation therapy.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Fatigue: persistent tiredness affecting daily activities. - Nausea: upset stomach often managed with anti‑emetics. - Alopecia: hair loss that may be temporary.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe infection: sepsis or pneumonia due to immune suppression. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Pulmonary toxicity: shortness of breath or interstitial lung changes. - Significant liver enzyme elevation: indicates hepatic injury.

Cabazitaxel requires careful monitoring and specific safety measures. - Monitor blood counts: perform regular CBC to detect neutropenia. - Assess hepatic function: check liver enzymes before each cycle. - Evaluate for hypersensitivity: observe for infusion‑related reactions. - Avoid in severe neutropenia: do not administer if ANC is critically low. - Use effective contraception: both male and female patients should use reliable birth control during treatment and for several months after. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Cabazitaxel may interact with other medicines and requires vigilance. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase cabazitaxel exposure. - Concurrent myelosuppressive agents: may exacerbate bone‑marrow toxicity. - Live vaccines: risk of infection due to immunosuppression. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticoagulants (e.g., warfarin): monitor coagulation parameters. - Diuretics: watch for electrolyte disturbances.